Prima BioMed Pre-Tax Profit Margin 2010-2021 | IMMP
Prima BioMed pre-tax profit margin from 2010 to 2021. Pre-tax profit margin can be defined as earnings before taxes as a portion of total revenue.
|Prima BioMed Pre-Tax Profit Margin Historical Data
||TTM Pre-Tax Income
||Medical - Biomedical and Genetics
Immutep Limited is a biotechnology company. It engaged in developing novel immunotherapy treatments for cancer and autoimmune disease. The company's product pipeline consists of eftilagimod alpha, IMP731, IMP701 and IMP761 which are in clinical stage. It operates primarily in Europe, Australia and the U.S. Immutep Limited, formerly known as Prima BioMed Ltd, is headquartered in Sydney, Australia.